Categories: Health

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

 | Source: MiNK Therapeutics

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Wednesday, June 18, 2025

Time: 9:30 a.m. ET

A live webcast and replay will be accessible from the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and at www.virtualshareholdermeeting.com/INKT2025.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Investor Contact
917-362-1370 
investor@minktherapeutics.com 

Media Contact
781-674-4428
communications@minktherapeutics.com

GlobeNews Wire

Recent Posts

Star Power in Action: Sunil Narine Takes Centre Stage in Parimatch’s New Game

Bringing brand ambassadors into the user journey has become a powerful way to create a…

16 hours ago

Parimatch Created Cricket Festival Boxes for Fans to Enjoy the Indian T20 League to the Fullest

As the Indian T20 League reaches its peak, Parimatch, the #1 global gaming platform is…

16 hours ago

World’s Best Glacier Photos Launch in Global “Walk of Water” Exhibition

Beauty and Peril of Vanishing Glaciers Taking Centre Stage in Onewater's Global Photography Exhibition, Urging…

16 hours ago

Guangdong launches four major international communication platforms

GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- On July 2, Guangdong officially launched four international communication…

16 hours ago

KuCoin Futures Ranks 4th Globally on CoinGlass’ Latest Derivatives Exchange List

VICTORIA, Seychelles, July 3, 2025 /PRNewswire/ -- KuCoin, a leading global cryptocurrency trading platform, is…

16 hours ago

SPJIMR’s PGDM Class of 2027 celebrates leadership, diversity, and purpose

New cohort embarks on a transformative journey in management and leadership MUMBAI, India, July 3,…

16 hours ago